Varricchio Frederick, Iskander John, Destefano Frank, Ball Robert, Pless Robert, Braun M Miles, Chen Robert T
Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration/NIH/DHHS, Rockville MD, USA.
Pediatr Infect Dis J. 2004 Apr;23(4):287-94. doi: 10.1097/00006454-200404000-00002.
The Vaccine Adverse Event Reporting System (VAERS) is administered by the Food and Drug Administration and CDC and is a key component of postlicensure vaccine safety surveillance. Its primary function is to detect early warning signals and generate hypotheses about possible new vaccine adverse events or changes in frequency of known ones. VAERS is a passive surveillance system that relies on physicians and others to voluntarily submit reports of illness after vaccination. Manufacturers are required to report all adverse events of which they become aware. There are a number of well-described limitations of such reporting systems. These include, for example, variability in report quality, biased reporting, underreporting and the inability to determine whether a vaccine caused the adverse event in any individual report. Strengths of VAERS are that it is national in scope and timely. The information in VAERS reports is not necessarily complete nor is it verified systematically. Reports are classified as serious or nonserious based on regulatory criteria. Reports are coded by VAERS in a uniform way with a limited number of terms using a terminology called COSTART. Coding is useful for search purposes but is necessarily imprecise. VAERS is useful in detecting adverse events related to vaccines and most recently was used for enhanced reporting of adverse events in the national smallpox immunization campaign. VAERS data have always been publicly available. However, it is essential for users of VAERS data to be fully aware of the strengths and weaknesses of the system. VAERS data contain strong biases. Incidence rates and relative risks of specific adverse events cannot be calculated. Statistical significance tests and confidence intervals should be used with great caution and not routinely. Signals detected in VAERS should be subjected to further clinical and descriptive epidemiologic analysis. Confirmation in a controlled study is usually required. An understanding of the system's defined objectives and inherent drawbacks is vital to the effective use of VAERS data in vaccine safety investigations.
疫苗不良事件报告系统(VAERS)由美国食品药品监督管理局和疾病控制与预防中心管理,是疫苗上市后安全性监测的关键组成部分。其主要功能是检测预警信号,并就可能出现的新疫苗不良事件或已知不良事件发生频率的变化提出假设。VAERS是一个被动监测系统,依靠医生和其他人员自愿提交接种疫苗后出现疾病的报告。制造商必须报告他们所知晓的所有不良事件。这类报告系统存在许多已被充分描述的局限性。例如,报告质量参差不齐、报告存在偏差、报告不完整以及无法在任何一份单独报告中确定疫苗是否导致了不良事件。VAERS的优势在于其覆盖全国且及时。VAERS报告中的信息不一定完整,也未经过系统核实。报告根据监管标准分为严重或非严重。VAERS使用一种名为COSTART的术语,以有限数量的术语对报告进行统一编码。编码有助于搜索,但必然不够精确。VAERS在检测与疫苗相关的不良事件方面很有用,最近被用于加强全国天花免疫接种运动中的不良事件报告。VAERS数据一直都是公开的。然而,VAERS数据的使用者必须充分了解该系统的优势和劣势。VAERS数据存在很大偏差。无法计算特定不良事件的发病率和相对风险。应极其谨慎地使用统计显著性检验和置信区间,且不能常规使用。在VAERS中检测到的信号应进行进一步的临床和描述性流行病学分析。通常需要在对照研究中进行确认。了解该系统的既定目标和固有缺陷对于在疫苗安全性调查中有效使用VAERS数据至关重要。